María Teresa G. C.
- Country
- Spain
- Department
- ES30002: Hematologia y Transfusión
Research Overview
- Phase II Study on Reinduction and Cessation of Ponatinib in Chronic Myelogenous Leukemia Patients in Molecular Response
- Phase 3 Multicenter Open-Label Randomized Study of Fedratinib Versus Best Available Therapy in Intermediate/High-Risk Myelofibrosis Post-Ruxolitinib Treatment
- A Phase 3 Randomized Open-Label Study of Imetelstat Versus Best Available Therapy in Intermediate-2 or High-Risk Myelofibrosis Refractory to JAK-Inhibitors
Data & Insights
Has run more than one trial at 66 of 191 partner sites.
Specializations
Hematologic Disorders
This investigator focuses on treating patients with various myeloid neoplasms, demonstrating particular expertise in managing complex blood disorders.
- Myelofibrosis (MF)
- Myelodysplastic Syndrome (MDS)
- Essential Thrombocythemia (ET)
The research interest extends to exploring novel therapeutic approaches for these challenging hematologic conditions.
Advanced Blood Disorders
The investigator specializes in the treatment of advanced myeloid disorders, with particular attention to conditions that overlap multiple disease classifications.
- Myeloid Neoplasms
- MDS/MPN Overlap Syndromes
Their work encompasses various therapeutic strategies for managing these complex hematologic conditions.
Therapeutic Innovation
The investigator's work centers on evaluating novel therapeutic compounds for blood disorders, with a focus on safety and tolerability assessments.
- Treatment Development
- Safety Evaluation
- Clinical Assessment
Their research aims to advance treatment options for patients with various myeloid disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.